Rare Disease Genetic Testing Market Size, Share, Growth Analysis, By Disease Type(Neurological Disease, Immunological Disorders), By Technology(Next-Generation Sequencing (NGS), Array Technology), By Specialty(Molecular Genetic Tests, Chromosomal Genetic Tests), By End-Use(Research Laboratories & CROs, Hospitals & Clinics), By Regional Scope(North America, Europe) - Industry Forecast 2024-2031

The market for Rare Disease Genetic Testing was estimated to be valued at US$ XX Mn in 2021.

The Rare Disease Genetic Testing Market is estimated to grow at a CAGR of XX% by 2028.

The Rare Disease Genetic Testing Market is segmented on the basis of Disease Type, Technology, Specialty, End-Use, Regional Scope.

Based on region, the Rare Disease Genetic Testing Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Rare Disease Genetic Testing Market are Quest Diagnostics Inc., Centogene N.V., Invitae Corp., 3billion, Inc., Arup Laboratories, Eurofins Scientific, Strand Life Sciences, Ambry Genetics, Perkin Elmer, Inc., Realm IDX, Inc., Macrogen, Inc., Baylor Genetics, Color Genomics, Inc., Health Network Laboratories, PreventionGenetics, Progenity, Inc., Coopersurgical, Inc., Fulgent Genetics Inc., Myriad Genetics, Inc., Laboratory Corporation of America Holdings, Opko Health, Inc., Artemis DNA.